反应详情

Following the procedures as described in Example 61 and starting with tert-butyl 4-(6-(6-(1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)pyridin-2-yl)-1,4-diazepane-1-carboxylate and oxetan-3-ylmethyl 4-methylbenzenesulfonate, 158 was obtained as a yellow solid (38 mg, 51%) over two steps. 1H-NMR (500 MHz, CD3OD) δ (ppm): 9.16-9.19 (m, 1H), 8.86-8.77 (m, 3H), 8.43-8.47 (m, 1H), 7.66-7.73 (m, 1H), 7.18-7.26 (m, 1H), 6.63-6.66 (m, 1H), 4.81-4.83 (m, 2H), 4.60-4.64 (m, 2H), 3.75-3.97 (m, 7H), 3.61-3.64 (m, 1H), 3.46-3.48 (m, 1H), 3.10-3.12 (m, 1H), 2.88-2.90 (m, 1H), 1.98-2.07 (m, 2H); MS (ESI) m/z: 431 [M+H]+.